Cevat Ilteris Kikili

Cevat Ilteris Kikili

Auto-generated profile, based on publicly available information

Cevat Ilteris Kikili

Department of Medical Oncology, Koç University School of Medicine, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2024 in Blood Coagulation & Fibrinolysis
Verified
Journal Article
Closed access
CKCevat İlTeriş Kikili
Cevat İlTeriş Kikili
DKDemet Kivanç
Demet Kivanç
DODamla Ortaboz
Damla Ortaboz
HÇHayriye Şentürk Çiftçi
Hayriye Şentürk Çiftçi
MÖMustafa Murat Özbalak
Mustafa Murat Özbalak
SBSevgi Kalayoğlu Beşişik
Sevgi Kalayoğlu Beşişik
Thrombotic thrombocytopenic purpura (TTP) is one of the rare group disorders classified as thrombotic microangiopathies (TMAs). Approximately 90% of TTP developed immune-mediation by the formation of antibodies against the enzyme ADAMTS-13. The exact cause is unknown. To establish an association between human leukocyte antigen (HLA) and autoimmune basis, as susceptibility or protection against the disease, we contributed a study aiming to evaluate the role of HLA in immune-mediated TTP (iTTP). Considering epidemiological factors such as age, sex, ethnicity, and geographical origins, we contributed the study in our country, Turkey, which consist of a very heterogeneous population. Patients’ data collection was retrospectively from electronic database on two University hospitals having big therapeutic apheresis service. Control arm was healthy people registered as stem cell donors matched in terms of age and sex. The frequency of HLA-DRB1 and HLA-DQB1 alleles between acquired TTP and the control group was compared using the chi-square method. Yates correction and logistic regression were performed on these results. A total of 75 iTTP patients and 150 healthy individuals enrolled to the study. HLA-DRB1∗11, HLA-DQB1∗03, HLA-DRB1∗11:01, HLA-DRB1∗14:01, HLA-DRB1∗13:05, HLA-DRB1∗11 + HLA-DQB1∗03 allele pair and HLA-DRB1∗15 + HLA- DQB1∗06 were proved to be susceptibility allele pairs for iTTP. HLA-DRB1∗15, HLA-DRB1∗01:01, HLA-DRB1∗07:01, HLA-DRB1∗13:01, HLA-DRB1∗14:54, HLA-DQB1∗05:01, HLA-DQB1∗02:02 and HLA-DRB1∗07 + HLA-DQB1∗02 allele pair were found to be protective against iTTP. Our findings support an association with iTTP across very heterogenous populations in Turkey.

18 June 2025 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
CKCevat İlteriş Kıkılı
Cevat İlteriş Kıkılı
MMMaide Müreva
Maide Müreva
CKCaner Kapar
Caner Kapar
BKBahadır Köylü
Bahadır Köylü
FKFatih Kemik
Fatih Kemik
DTDeniz Tural
Deniz Tural

24 March 2025 in Immunotherapy
Verified
Journal Article
Closed access
BKBahadır Köylü
Bahadır Köylü
CKCevat İlTeriş Kıkılı
Cevat İlTeriş Kıkılı
ÖDÖner Dikensoy
Öner Dikensoy
FSFatih Selçukbiricik
Fatih Selçukbiricik
Immune-related adverse events typically occur during the early phases of immune checkpoint inhibitor therapy. However, late-onset immune-related adverse events can still arise long after the immune checkpoint inhibitor therapy has ended. Immune checkpoint inhibitor-related pneumonitis warrants special attention for risk assessment and early detection due to its potential for serious outcomes, including hospitalization and death. Despite its rarity, late-onset immune checkpoint inhibitor-related pneumonitis should be considered in the differential diagnosis for dyspnea in patients with a history of immune checkpoint inhibitor therapy to prevent morbidity and mortality. In this case report, we present a case of an 84-year-old female patient suffering from locally advanced triple-negative breast cancer and late-onset immune checkpoint inhibitor-related pneumonitis requiring hospitalization 104 days after the last cycle of pembrolizumab. Following successful treatment of late-onset immune checkpoint inhibitor-related pneumonitis with corticosteroids, a recurrence of immune checkpoint inhibitor-related pneumonitis occurred a month later. Corticosteroid therapy was reinitiated, gradually tapered after radiological improvement, and eventually discontinued. The patient remains in remission from breast cancer. For patients with a history of immune checkpoint inhibitor therapy, medical vigilance, accurate diagnosis, and timely management of late-onset immune checkpoint inhibitor-related pneumonitis are crucial.

22 April 2026 in The Prostate
Verified
Journal Article
Open access
CKCevat İlTeriş Kıkılı
Cevat İlTeriş Kıkılı
CKCaner Kapar
Caner Kapar
FYFeyyaz Hazar Yağmur
Feyyaz Hazar Yağmur
EAEsra Arslan
Esra Arslan
BKBahadır Köylü
Bahadır Köylü
DTDeniz Tural
Deniz Tural
Purpose: Previous studies have demonstrated an association between PSMA‐PET SUVmax and poorer survival outcomes in patients with mCRPC. However, limited data are available in mHSPC. We aim to investigate the relationship between baseline PSMA‐PET SUVmax and rPFS in patients with mHSPC. Methods: The optimal SUVmax cut‐off for rPFS was determined using Harrell's C‐index. Baseline characteristics were compared using the χ ² test between the groups and survival analyses for rPFS were performed. Results: Data from 165 patients were retrospectively analyzed, with a median follow‐up of 44 months (mo) (range: 9–103 mo). A total of 17.16 was identified as the optimal SUVmax cutoff. Baseline characteristics were compared whit this threshold. SUVmax higher patients showed poor ECOG PS, high denovo metastases, high volume, higher ALP, and high median PSA level. The median rPFS for the entire cohort was 34.3 mo (95% CI: 22.0–46.5 mo). In univariate analysis, patients with higher SUVmax had a median rPFS of 23 mo versus 60.4 mo in those with low SUVmax ( p < 0.001). ALP normal versus higher (41.5 vs. 20.7 mo, p = 0.011), hemoglobin < 12 g/dL versus ≥ 12 g/dL (21.2 vs. 48.4 mo, p = 0.004), low versus high tumor volume (60.4 vs. 23 mo, p = 0.004) and PSA ≥ 35 ng/mL versus PSA < 35 ng/mL (23.9 mo vs NR, p = 0.030). Furthermore, patients not receiving ARPIs therapy exhibited inferior rPFS (ADT‐alone:20.7 mo vs. ADT + docetaxel:19.2 mo vs. ADT plus ARPIs: 48.4 mo, p = 0.002). Conclusion: We demonstrated that high SUVmax has a negative prognostic impact on rPFS in mHSPC.

23 July 2025 in Turkish Journal of Hematology
Verified
Journal Article
Open access
SKSema Karakuş
Sema Karakuş
ŞBŞule Mine Bakanay
Şule Mine Bakanay
SBSevgi Kalayoglu Besısık
Sevgi Kalayoglu Besısık
AEAhmet Emre Eskazan
Ahmet Emre Eskazan
MAMEHMET ORHAN AYYILDIZ
MEHMET ORHAN AYYILDIZ
MAMuhlis Cem Ar
Muhlis Cem Ar
This study aimed to investigate the clinical manifestations, treatment patterns and clinical outcomes in patients with iTTP across Türkiye via an interim analysis of the Turkish iTTP registry. A total of 215 patients with iTTP (median age at diagnosis 41 years, 58.6% female) diagnosed between 2001 and 2023 were retrospectively analyzed in the interim analysis of the prospective noninterventional observational multicenter iTTP registry study conducted at 19 tertiary hematology centers. Data on patient demographics, disease characteristics on initial admission, treatment characteristics, and responses, exacerbations/relapses, and the survival outcome were registered via electronic case report forms. Infection (15.0%), new drug initiation (9.7%), and pregnancy/postpartum (6.3%) within 3 weeks before diagnosis were the most prevalent potential triggers. Patients presented more commonly with systemic/constitutional (fatigue 68.8%; fever 18.1%) and neurologic (headache 40.0%, vertigo 32.1%), followed by hemorrhagic, gastrointestinal, renal, and cardiovascular manifestations. Based on the PLASMIC risk scoring, 77.8% of patients were initially at high risk for TTP. The initial treatment was commenced within the first 48 hours of hospital admission in 64.1% of patients (36.2% on the day of admission). Treatment was mainly based on TPE exchange (92.1%) and steroids (63.7%), while rituximab was used in 15.8% of patients. The clinical response rate was 79.9%, and clinical remission was achieved in 68.2% of patients. As for the ADAMTS13 levels, partial and complete responses were achieved in 17.7% and 14.6%, respectively. During a median of 30 months (range, 0.1 to 262.4 months) follow-up, 35 patients experienced exacerbations/relapses. Mortality occurred in 11 (5.5%) patients and was found to be disease-related in 6 (3.0%). This interim analysis of the nationwide Turkish iTTP registry study provided valuable data on the real-world clinical practice in the diagnosis and management of iTTP at different hematology clinics across the country.

1 June 2026 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
CKCevat İlTeriş Kıkılı
Cevat İlTeriş Kıkılı
MAMurat Araz
Murat Araz
YÜYüksel Ürün
Yüksel Ürün
MBMert Başaran
Mert Başaran
NŞNur Şener
Nur Şener
DTDeniz Tural
Deniz Tural